Trovagene Precision Cancer Monitoring (PCM) provides noninvasive and quantitative alternatives to biopsy and imaging for tracking specific oncogene mutations over time, with the flexibility of urine- and blood-based testing.
As tumor cells die through treatment or natural processes, small fragments of DNA are released into the blood and—as Trovagene was first to discover—into the urine. Measuring this circulating tumor DNA (ctDNA) offers a new way to track cancer-related gene mutations at the molecular level.
Liquid biopsies have shown great promise in detecting and monitoring cancer. One contender, Trovagene, tells Clinica why it believes it has the edge over other companies in the space. Read More (subscription required).
The Wall Street Transcript spoke with Trovagene's CEO, Dr. Antonius Schuh, for its annual life sciences report. The interview provides an overview of Trovagene's business model, steps to commercialization and numerous collaborations and partnerships in process. The interview also reviews the company's key objectives for 2015, potential business risks, and the compelling investment opportunity that exists. Read More.
Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are characterized by a high frequency of BRAF V600E mutations, which may occur in approximately 50% of patients with these diseases, and which are responsive to treatment with BRAF inhibitors such as vemurafenib. Read More.